Emeset 4 ODT

Product Overview

Emeset 4 ODT is an antiemetic medication featuring Ondansetron (4mg) in orally disintegrating tablet form. Designed for rapid action, this specialized formulation dissolves instantly on the tongue without requiring water, offering convenient relief from nausea and vomiting for active patients.

Uses

Emeset 4 ODT is primarily indicated for:

• Preventing chemotherapy-induced nausea and vomiting (CINV)
• Managing radiation therapy-related nausea
• Preventing postoperative nausea and vomiting (PONV)

The medication functions by selectively blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.

How to Use

Administration Instructions:

1. Place tablet on tongue immediately after removal from blister
2. Allow tablet to dissolve completely (do not chew/swallow whole)
3. No water required for administration

For optimal results in chemotherapy patients, take 30 minutes before treatment as prescribed. Follow your healthcare provider’s specific dosing schedule.

Mechanism of Action

Ondansetron, the active component of Emeset 4 ODT, is a selective 5-HT3 receptor antagonist. It prevents serotonin from binding to receptors in both the central nervous system (area postrema) and peripheral nervous system (enteric neurons), thereby interrupting the vomiting reflex pathway.

Dosage and Administration

Standard Dosing Guidelines:

Indication	Dosage	Timing
Chemotherapy	8mg	30 minutes pre-treatment, then q8h for 1-2 days
Radiation Therapy	8mg	1-2 hours pre-treatment
Surgery	16mg	1 hour pre-anesthesia

Note: Always follow physician-prescribed regimen

Key Benefits

• Rapid-dissolving formulation for immediate relief
• Waterless administration ideal for patients with swallowing difficulties
• Proven efficacy across multiple emetogenic challenges
• Flexible administration (with or without meals)
• Favorable safety profile with minimal adverse effects

Potential Adverse Effects

Most common adverse reactions (≥5% incidence):

• Headache (15-20%)
• Constipation (5-10%)
• Transient dizziness (5-8%)
• Mild drowsiness (3-5%)

These effects are typically self-limiting. Consult your healthcare provider if symptoms persist beyond 48 hours.

Important Considerations

Special Populations:

• Use caution in patients with hepatic impairment (dose adjustment may be required)
• Monitor cardiac rhythm in patients with pre-existing QT prolongation
• Not recommended for children under 4 years

Safety Warnings

Contraindications:

• Hypersensitivity to ondansetron or components
• Concomitant use with apomorphine

Precautions:

• May mask progressive ileus symptoms
• Potential serotonin syndrome risk with other serotonergic drugs

Storage Conditions

Optimal Storage:

• Temperature: 15-30°C
• Protect from moisture and light
• Keep in original blister packaging until use
• Store in child-resistant container

Medical Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. While we strive for accuracy, this content is not exhaustive and may not reflect the most current medical information. Always consult your healthcare provider regarding any medical condition or treatment. This material is intended to complement, not replace, professional medical judgment.